Home

DiaMedBase 

Diabetes Medicinal Plant Database

Browse    A B C D E F G H I J K L M N O P Q R S T U V W X Y Z     Plants List
Lactuca
Lagerstroemia
Larrea
Laurus
Lavandula
Leguminous
Lepechinia
Lepidium
Leucas
Loranthus
Luffa
Lupinus
Lycium
Lygos
 
DiaMedBase ID   DMPLt368
Medicinal Plant   Larrea tridentata
Plant part(s)   Not available
Objective  

To study  the ability of a pure compound isolated from the creosote bush (Larrea tridentata) to lower plasma glucose concentration in two mouse models of type 2 diabetes

Journal Source   Eur J Pharmacol. 1998; 346(1):77-79
Title  

Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush (Larrea tridentata)

Authors  

Luo J, Chuang T, Cheung J, Quan J, Tsai J, Sullivan C, Hector RF, Reed MJ, Meszaros K, King SR, Carlson TJ, Reaven GM

Address   Shaman Pharmaceuticals, South San Francisco, CA 94080-4812, USA
Abstract  

An ethnomedically-driven approach was used to evaluate the ability of a pure compound isolated from the creosote bush (Larrea tridentata) to lower plasma glucose concentration in two mouse models of type 2 diabetes. The results indicated that plasma glucose concentration fell approximately 8 mmol/l in male C57BL/ks-db/db or C57BL/6J-ob/ob mice following the oral administration of masoprocol (nordihydroguaiaretic acid), a well known lipoxygenase inhibitor. The decline in plasma glucose concentration following masoprocol treatment in the mice was achieved without any change in plasma insulin concentration. In addition, oral glucose tolerance improved and the ability of insulin to lower plasma glucose concentrations was accentuated in masoprocol-treated db/db mice. These data raise the possibility that masoprocol, or other lipoxygenase inhibitors, represents a new approach to the pharmacological treatment of Type 2 diabetes.

Diseases   Disease Link

Copyright © 2006 ProGene Biosciences
   Last modified: March, 2006
   info@progenebio.in